🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The video podcast of my latest #HealthcareUnfiltered is right here. Two cardiologists Anish Koka, MD and Andrew Foy debate a timely critical topic. Should government be in the business of negotiating drug prices? Watch/listen/& engage. As always, pls let me know what you think.

🎯🎯🎯

The first MAHA Report is out. I urge everyone in healthcare and biomedical research to read it soon and consider its implications. Some hard truths, some arguable assertions, many points on which we can all agree. Regardless, this document is going to be foundation of USG health

I just recorded an excellent podcast with Andrew Foy Mohammed Ruzieh, MD on the below HF trials. Coming Friday on Cardiology Trials I learn so much from these two. Teaser: there is a bunch of nuance in our GDMT evidence

Good move. When academic institutions take public positions on controversial topics outside of their mission, they chill campus speech and marginalize people with different views. Institutional neutrality is the right position. Srihari S. Naidu, MD Sensible Medicine

Enjoyed this debate/discussion from all participants. Would encourage anyone interested in CV health to watch it.

Perhaps “academics” is a mindset not dependent on what the sign on the outside of a building says 👇🏻

61% voted to downgrade or retire beta-blocker recommendation and 39% to wait for additional evidence from ongoing trials 👇 x.com/kaulcsmc/statu… For deeper dive into current evidentiary support (or lack thereof) 👇 jacc.org/doi/10.1016/j.… JACC Journals John Mandrola, MD Andrew Foy

Naysayers predict doom at FDA w new leadership. Yet within weeks, Marty Makary MD, MPH Vinay Prasad MD MPH approve a new COVID vaccine and get a promise of a proper RCT And they speak w utter clarity and humility about net benefit/harms of *ALL* Medical Rxs. Can we now give them a chance?

The first question to ask when reviewing a study is whether it is science or marketing?

Nice paper. This is good information to know. Good use of clinical trial dataset.

We all want NIH to succeed and I believe that dissent in science is productive. However, the Bethesda Declaration has some fundamental misconceptions about the policy directions NIH has taken in recent months. 🧵1/5

In this video, Paul Offit makes the case for continuing to recommend primary covid vaccination for all US children. At 4:45, he make a striking statement that "if you are asking all doctors in this country to know all the primary data [behind a medical recommendation], that is

NO ASSOCIATION BETWEEN PREPROCEDURAL FASTING AND WITNESSED PULMONARY ASPIRATION A SYSTEMATIC REVIEW AND META-ANALYSIS I want to bring to everyone's attention the publication of an article we have been working on for some time. Ever been annoyed by having cases cancelled because

🧵Part 2: Journal ignores evidence of misconduct in studies of anti-clotting drug, ticagrelor After publishing two key platelet studies, Circulation has deflected responsibility amid evidence of scientific misconduct—missing data, outcome switching, and authorship irregularities.

I’ve been studying medical studies for more than a decade, and Vinay Prasad MD MPH is one of the best at judging evidence I have seen. He’s a huge asset for proper regulation. Highest confidence 👇🏻

Realistic, value-based medicine. No obsession with specific tools — but solving problems and truly sharing decisions. Thanks for this article John Mandrola, MD , Adam Cifu, Vinay Prasad MD MPH and Andrew Foy . Sad that we need definitions for a mindset that should be default.

True for documenting clinic visits too...

We live in a world of endless quality metrics. Adding another makes no sense. This metric doesn't even meet the definition of a performance measure.

This is a great discussion of the BEST trial (beta-blockade in systolic heart failure) - by Andrew Foy Not many know this trial which was negative. Andrew discusses why the results differ from other BB trials New trials’ reviews coming soon w/ Andrew Foy and John Mandrola, MD